Teduglutide (Gattex)

FDA-approved context Healing & Recovery 3 sources

Teduglutide is a glucagon-like peptide-2 (GLP-2) analog that promotes the growth and repair of the intestinal lining. It is FDA-approved for the treatment of Short Bowel Syndrome (SBS) in patients who are dependent on parenteral support, helping them reduce or eliminate the need for intravenous fluids and nutrition.

01Dosing reference

Amount

0.05 mg/kg body weight

Frequency

Once daily

Cycle

Continuous daily use as prescribed

Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

GLP-2 Receptor Activation

Binds to GLP-2 receptors located on enteroendocrine cells in the gut lining.

Intestinal Mucosal Growth

Stimulates the proliferation of intestinal epithelial cells, increasing villus height and crypt depth.

Enhanced Absorption

Increases the absorptive surface area of the intestine, improving the uptake of fluids and nutrients.

03Human evidence

Significant reductions in the volume of parenteral nutrition and intravenous fluids required by SBS patients.

Demonstrated in Phase 3, randomized, placebo-controlled clinical trials involving adult patients dependent on parenteral support.

A portion of patients were able to completely wean off parenteral support after long-term treatment.

Observed in long-term extension studies where patients received continuous daily subcutaneous injections.

04Preclinical evidence

Enhanced intestinal adaptation and mucosal hyperplasia.

Observed in animal models of massive bowel resection, showing structural improvements in the remaining gut.

Decreased intestinal inflammation and improved mucosal healing.

Demonstrated in rodent models of colitis and inflammatory bowel disease.

05What is known vs. unknown

Reasonably established

Teduglutide is a 33-amino acid GLP-2 analog with a longer half-life than endogenous GLP-2 due to a single amino acid substitution.
It significantly reduces the need for parenteral nutrition in patients with Short Bowel Syndrome.
The medication is administered via daily subcutaneous injection.
It promotes structural changes in the gut, including increased villus height and improved absorptive capacity.

Unknowns & limits

Long-term safety regarding the potential for promoting the growth of intestinal polyps or tumors requires ongoing monitoring.
The effects of discontinuing the medication, which can lead to a rapid loss of the newly grown intestinal tissue and a return to baseline absorption levels.

06Safety & regulatory context

Regulatory statusTeduglutide (Gattex) is FDA-approved for adults and pediatric patients with Short Bowel Syndrome who are dependent on parenteral support. Common side effects include abdominal pain, nausea, upper respiratory tract infection, and injection site reactions. Due to its growth-promoting effects, there is a theoretical risk of accelerating the growth of existing intestinal tumors or polyps, so colonoscopy monitoring is recommended before and during treatment. It is contraindicated in patients with active gastrointestinal malignancies.

07Compared with GLP-1 agonists (e.g., Semaglutide)

Teduglutide (Gattex) vs. GLP-1 agonists (e.g., Semaglutide)

Key difference

While GLP-1 agonists primarily target insulin secretion, gastric emptying, and appetite for diabetes and weight loss, GLP-2 analogs like Teduglutide specifically target intestinal growth and nutrient absorption.

When researchers discuss each

GLP-1 is discussed in the context of metabolic syndrome and obesity, whereas GLP-2 is discussed for intestinal rehabilitation and malabsorption disorders.

08Glossary

Short Bowel Syndrome (SBS)

A malabsorption disorder caused by the surgical removal of a large portion of the small intestine.

Parenteral Nutrition

Intravenous feeding that bypasses the digestive system to provide nutrients directly into the bloodstream.

GLP-2

Glucagon-like peptide-2, a naturally occurring hormone that promotes the growth and maintenance of the intestinal lining.

09Knowledge check

Q1What is the primary mechanism of action of Teduglutide?

Q2What is a major clinical benefit of Teduglutide for patients with Short Bowel Syndrome?

Q3Which documented limitation about teduglutide's long-term use is stated in the dossier?

Q4Which statement best reflects the comparison between GLP-2 analogs like teduglutide and GLP-1 agonists described in the dossier?

Q5According to the dossier, which safety-related recommendation or regulatory point applies to teduglutide?

10Sources

More in Healing & Recovery

See all

BPC-157

Healing & Recovery

Early human

BPC-157 is a synthetic peptide sequence based on a protective compound naturally found in human gastric juice. Research suggests it has significant regenerative properties, promoting the healing of tendons, ligaments, muscles, and the gastrointestinal tract by accelerating angiogenesis and modulating growth factors.

250-500 mcg

TB-500 (Thymosin Beta-4)

Healing & Recovery

Early human

TB-500 is a synthetic version of the naturally occurring peptide Thymosin Beta-4. Research indicates it plays a crucial role in tissue repair, wound healing, and reducing inflammation by upregulating actin, a vital protein for cell structure and movement.

2.0 - 2.5 mg per injection

KPV

Healing & Recovery

Early human

KPV (Lys-Pro-Val) is a naturally occurring tripeptide derived from alpha-melanocyte-stimulating hormone (alpha-MSH). Research highlights its potent anti-inflammatory and antimicrobial properties, making it a promising candidate for conditions like inflammatory bowel disease, skin disorders, and wound healing.

200-500 mcg/day

Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.